CN105732379A - Diarylheptanoid compound and its preparation method and use - Google Patents
Diarylheptanoid compound and its preparation method and use Download PDFInfo
- Publication number
- CN105732379A CN105732379A CN201410742088.4A CN201410742088A CN105732379A CN 105732379 A CN105732379 A CN 105732379A CN 201410742088 A CN201410742088 A CN 201410742088A CN 105732379 A CN105732379 A CN 105732379A
- Authority
- CN
- China
- Prior art keywords
- bioactive
- preparation
- diphenyl heptane
- heptane compound
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of medicines and discloses a diarylheptanoid compound and its preparation method and use in preparation of a drug or food for treating psoriasis. The diarylheptanoid compound with biological activity has a structure shown in the formula I. The diarylheptanoid compound with biological activity is named as (E)-3-acetoxy-1, 7-di(4-hydroxyphenyl)-6-heptylene, has biological activity of inhibiting human T cell lymphoma cell line HH cell proliferation and can be used in preparation of a drug or food for treating psoriasis.
Description
Technical field
The invention belongs to pharmaceutical technology field, particularly to a kind of diphenyl heptane compound and preparation method thereof and the application in preparation treatment psoriasis or food.
Background technology
Guangxi zedoary is the dry rhizome of Zingiberaceae curcuma, is one of conventional Chinese medicine.Within 2005, version Chinese Pharmacopoeia is recorded: Rhizoma Curcumae is the dry rhizome of zingiberaceous plant Rhizoma Curcumae (CurcumaphaeocaulisValeton), Guangxi zedoary (CurcumakwangsiensisS.G.LeeetC.F.Liang) or RADIX CURCUMAE (CurcumawenyujinY.H.ChenetC.Ling), mainly originates in the places such as Guangxi, Sichuan, Zhejiang, Fujian.Chinese medicine and pharmacy theory is thought, its property acrid, bitter, warm, has circulation of qi promoting removing blood stasis, effect of removing food stagnancy pain relieving.Cure mainly that vim and vigour are pained, eating accumulation, abdominal distention, amenorrhea due to stagnation of blood, dysmenorrhea, traumatic injury.Curcuma typically contains two big active component, i.e. compound in diphenyl heptane class and volatile oil compounds, in addition, possibly together with compositions such as Diterpenes, polysaccharide, phenolic acids and sterols.Have been demonstrated that compound in diphenyl heptane class and volatile oil composition are its primary bioactive components.Chinese scholars by pharmacological experiment confirm compound in diphenyl heptane class there is emesis, tuberculosis, protect the liver, anticoccidial, antifungal, anticancer and suppress the multiple biological activitys such as prostaglandin synthesis.
Psoriasis is a kind of commonly encountered diseases in department of dermatologry, frequently-occurring disease, its cause of disease complexity and recurrent exerbation, is always up the difficult medical problem in the puzzlement whole world.Its histopathology feature main manifestations is epidermal keratinocytes cellulation abnormality proliferation and differentiation, and with the infiltration of scytitis cell.At present, the method for this disease of western medical treatment mainly has four aspects: medicine for external use is treated, such as steroid hormone, tacrolimus and vitamin D 3-derivatives etc.；Systemic drug is treated, such as tretinoin medicines, methotrexate and ciclosporin etc.；Physiotherapy, such as narrow-band UVB irradiation treatment；Biological preparation, such as Embrel, Ah method's Saite and efalizumab etc..But these therapies are all not fee from the problem of drug dependence and recurrence, and simultaneity factor medicine brings again bigger side effect, and biological preparation is expensive, and these all limit the clinical practice of these therapies.Psoriasis Treated by TCM method is various, is administered flexible and changeable, and curative effect is better, and side effect is little, and has cheap advantage concurrently, receives significant attention in clinical treatment psoriasis.But Chinese medicine compound composition is indefinite, and it is qualitative and method for evaluating safety is perfect not, limits its clinical expansion and application.Therefore, from Chinese medicine, isolate the Chinese medicine monomer of determined curative effect, be the main direction of studying of Psoriasis Treated by TCM from now on.
Summary of the invention
In order to overcome shortcoming and the deficiency of above-mentioned prior art, the primary and foremost purpose of the present invention is in that to provide one to have bioactive diphenyl heptane compound.
Another object of the present invention is in that to provide a kind of above-mentioned preparation method with bioactive diphenyl heptane compound.
Still a further object of the present invention is in that providing above-mentioned has the application in preparation treatment psoriasis or food of the bioactive diphenyl heptane compound.
The purpose of the present invention is realized by following proposal:
One has bioactive diphenyl heptane compound, has structure shown in following formula I:
The described chemical name with bioactive diphenyl heptane compound is (E)-3-acetoxyl group-1,7-two (4-hydroxy phenyl)-6-heptene.
The present invention has bioactive diphenyl heptane compound and can prepare from plant extract or synthetic method.
Described synthetic method refers to be synthetically derived with this compound analog.
Present invention also offers a kind of above-mentioned preparation method with bioactive diphenyl heptane compound, comprise the following specific steps that:
(1) Rhizoma Curcumae rhizome is taken, extract with 95v/v% alcohol-water, extract separates through HP-20 macroporous adsorbent resin column chromatography, successively with water, 30v/v% ethanol, 90～100v/v% ethanol gradient elution, collect eluent, concentrating under reduced pressure respectively, obtain water elution position, 30v/v% alcohol elution, 90～100v/v% alcohol elution；
(2) 90～100v/v% alcohol elution of step (1) is taken, separate through silica gel column chromatography, use chloroform-methanol gradient elution, collecting chloroform-methanol ratio is the fraction of 9:1, through ODS pillar layer separation, using methanol-water gradient elution, collecting methanol-water ratio is the fraction of 7:3, separate through preparative liquid chromatography HPLC, obtain that there is bioactive diphenyl heptane compound.
In above-mentioned preparation method, step (2) described preparative liquid chromatography, with ratio be 65:35 methanol-water for mobile phase, detection wavelength is 208nm and 220nm, flow velocity is 12mL/min, and the bioactive diphenyl heptane compound retention time in preparation liquid phase that has of the present invention is 20.3min.
The bioactive diphenyl heptane compound that has of the invention described above has the biological activity suppressing HTL's cell line HH cell proliferation, can be applicable in preparation preventing and treating psoriasis or food.
The described at least one having in bioactive diphenyl heptane compound ((E)-3-acetoxyl group-1,7-two (4-hydroxy phenyl)-6-heptene), its pharmaceutical salts and solvate being applied in preparation preventing and treating psoriasis or food middle finger medicine or food containing the present invention.Known, the solvation form of compound and salt generally have no effect on the biologic activity of compound self.
Described medicine contains one or more pharmaceutically acceptable carrier or excipient.
The present invention has such advantages as relative to prior art and beneficial effect:
Present invention separation and Extraction from Guangxi zedoary rhizome obtains a kind of new diphenyl heptane compound, (E)-3-acetoxyl group-1,7-bis-(4-hydroxy phenyl)-6-heptene, by the testing in vitro to HTL's cell line HH cell proliferation, determine that it has good Inhibit proliferaton effect, and in dose-effect relationship, thus suitable in preparation preventing and treating psoriasis or food.
Accompanying drawing explanation
Fig. 1 is that diphenyl heptane compound of the present invention is to HTL's cell line HH cell inhibitory effect design sketch.
Detailed description of the invention
Below in conjunction with embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
Hyclone (FBS) is purchased from Hyclone company；RPMI1640 culture medium, HTL's cell line HH cell are purchased from ATCC company；CCK-8 cytoactive detection kit is purchased from east Renhua subject skill (Shanghai) Co., Ltd..
Embodiment 1: the separation and Extraction of the diphenyl heptane compound of the present invention
Take dry Guangxi zedoary rhizome, extract with 95v/v% alcohol-water, extract separates through HP-20 macroporous adsorbent resin column chromatography, successively with water, 30v/v% ethanol, 90～100v/v% ethanol gradient elution, collect each eluent respectively, concentrating under reduced pressure, obtains water elution position, 30v/v% alcohol elution, 90～100v/v% alcohol elution；Take 90～100v/v% alcohol elution, separate through silica gel column chromatography, use chloroform-methanol gradient elution, collect the fraction E that chloroform-methanol ratio is 9:1, fraction E, through ODS pillar layer separation, uses methanol-water gradient elution, collects the fraction E-6 that methanol-water ratio is 6:4, fraction E-6 separates through preparation liquid phase HPLC, obtains the compounds of this invention.
In above-mentioned preparation method, step (2) described preparative liquid chromatography, with ratio be 65:35 methanol-water for mobile phase, detection wavelength is 208 and 220nm, flow velocity is 12mL/min, retention time in preparation liquid phase is 20.3min, and separating obtained solution dries, and obtains the compounds of this invention 57.4mg.
Embodiment 2: the structural identification of the compounds of this invention
The compound that the present invention obtains is yellow oil.Negative source HR-ESI-LTQ/Orbitrap-MS shows m/z [M-H]-339.1584, high resolution mass spectrum provides molecular formula C21H24O4。
1nullH-NMR data，Chemical shift (multiplicity during 500MHz，Coupling constant)，Coupling constant unit is Hz:2.52 (2H,m,H-1),1.82(2H,m,H-2),4.93(1H,m,H-3),1.70(2H,m,H-4),2.16(2H,m,H-5),5.98(1H,dt,16.0,7.5,H-6),6.25(1H,d,16.0,H-7),6.97(4H,d,8.5,H-2’,6’),6.68(4H,d,8.5,H-3’,5’),7.15(4H,d,8.5,H-2”,6”),6.69(4H,d,8.5,H-3”,5”),2.00(3H,s,OCH3)。
13C-NMR data, chemical shift during 125MHz: 32.1 (C-1), 37.6 (C-2), 75.2 (C-3), 35.4 (C-4), 30.3 (C-5), 127.7 (C-6), 131.6 (C-7), 131.0 (C-1 '), 128.5 (C-2 ', 6 '), 116.5 (C-3 ', 5 '), 157.9 (C-4 '), 133.9 (C-1 "); 130.6 (C-2 ", 6 "), 116.4 (C-3 "; 5 "), 156.7 (C-4 "), 173.2 (C=O), 21.5 (OCH3)。
By MS,1H-NMR and13It is (E)-3-acetoxyl group-1,7-two (4-hydroxy phenyl)-6-heptene that C-NMR confirms structure.
Embodiment 3: the compounds of this invention In Vitro Anti HTL's cell line HH cell proliferation detects
1600rpm, 3min are centrifuged and collect the HTL's cell line HH cell being in exponential phase, and resuspended by 1640 culture medium containing 10%FBS；In 96 orifice plates, every hole adds the HH cell suspension of 100 μ L, to final concentration of 2 × 104Individual cell per well.Embodiment 1 separates the compound obtained and is dissolved in DMSO, is configured to the storage liquid of final concentration of 10mM；During use, take storing in the RPMI1640 culture medium that liquid joins 90 μ L of 10 μ L, be diluted to the use liquid of 1mM；Meanwhile, take the DMSO of 10 μ L to join in the RPMI1640 culture medium of 90 μ L and use liquid as negative control group.The liquid that uses taking 0,1,2,2.5,3,3.5,5,10 μ L respectively adds the Concentraton gradient making 0,10,20,25,30,35,50,100 μMs to 96 orifice plates；Meanwhile, negative control group adds the negative control group use liquid of respective volume.37 DEG C, 5%CO2Cultivating 24h in incubator, every hole adds the CCK-8 of 10 μ L, and in incubator, lucifuge cultivates 4h, uses microplate reader to measure the light absorption value of 450nm, and convert suppression ratio, uses the mapping of Graphpad software, and result is shown in Fig. 1.
Suppression ratio %=[1-(experimental group OD/ matched group OD)] × 100%
As seen from Figure 1, by using CCK-8 kit measurement cell viability, it has been found that compared with negative control group, after the compounds of this invention processes, HH cell proliferation receives obvious suppression.
Above-described embodiment is the present invention preferably embodiment; but embodiments of the present invention are also not restricted to the described embodiments; the change made under other any spirit without departing from the present invention and principle, modification, replacement, combination, simplification; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (7)
1. one kind has bioactive diphenyl heptane compound, it is characterised in that have structure shown in following formula I:
2. according to claim 1 have bioactive diphenyl heptane compound, it is characterised in that: described in there is bioactive diphenyl heptane compound prepare from plant extract or synthetic method.
3. the preparation method with bioactive diphenyl heptane compound according to any one of claim 1～2, it is characterised in that comprise the following specific steps that:
(1) Rhizoma Curcumae rhizome is taken, extract with 95v/v% alcohol-water, extract separates through HP-20 macroporous adsorbent resin column chromatography, successively with water, 30v/v% ethanol, 90～100v/v% ethanol gradient elution, collect eluent, concentrating under reduced pressure respectively, obtain water elution position, 30v/v% alcohol elution, 90～100v/v% alcohol elution；
(2) 90～100v/v% alcohol elution of step (1) is taken, separate through silica gel column chromatography, use chloroform-methanol gradient elution, collecting chloroform-methanol ratio is the fraction of 9:1, through ODS pillar layer separation, using methanol-water gradient elution, collecting methanol-water ratio is the fraction of 7:3, separate through preparative liquid chromatography HPLC, obtain that there is bioactive diphenyl heptane compound.
4. the preparation method with bioactive diphenyl heptane compound according to claim 3, it is characterized in that: step (2) described preparative liquid chromatography, with ratio be 65:35 methanol-water for mobile phase, detection wavelength be 208nm and 220nm, flow velocity is 12mL/min.
5. the bioactive diphenyl heptane compound that has according to any one of claim 1～2 prevents and treats the application in psoriasis or food in preparation.
6. according to claim 5 have the application in preparation preventing and treating psoriasis or food of the bioactive diphenyl heptane compound, it is characterised in that: described is applied in preparation preventing and treating psoriasis or food middle finger medicine or food containing the described at least one having in bioactive diphenyl heptane compound, its pharmaceutical salts and solvate.
7. according to claim 5 have the application in preparation preventing and treating psoriasis or food of the bioactive diphenyl heptane compound, it is characterised in that: described medicine contains one or more pharmaceutically acceptable carrier or excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410742088.4A CN105732379B (en) | 2014-12-08 | 2014-12-08 | A kind of diphenyl heptane compound and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410742088.4A CN105732379B (en) | 2014-12-08 | 2014-12-08 | A kind of diphenyl heptane compound and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105732379A true CN105732379A (en) | 2016-07-06 |
| CN105732379B CN105732379B (en) | 2018-12-28 |
Family
ID=56236872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410742088.4A Active CN105732379B (en) | 2014-12-08 | 2014-12-08 | A kind of diphenyl heptane compound and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105732379B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979366A (en) * | 2010-09-26 | 2011-02-23 | 沈阳药科大学 | Diarylheptanoid compounds in curcuma zedoary and medicinal application thereof |
-
2014
- 2014-12-08 CN CN201410742088.4A patent/CN105732379B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979366A (en) * | 2010-09-26 | 2011-02-23 | 沈阳药科大学 | Diarylheptanoid compounds in curcuma zedoary and medicinal application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 宋智琦等: "《莪术油霜剂外用治疗银屑病的药效学及作用机制研究》", 《中国皮肤性病学杂志》 * |
| 杨雷香等: "《生姜中二苯庚烷类化合物的抗氧化和细胞毒活性研究》", 《中国中药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105732379B (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development | |
| Moon et al. | Isoimperatorin, cimiside E and 23-O-acetylshengmanol-3-xyloside from Cimicifugae rhizome inhibit TNF-α-induced VCAM-1 expression in human endothelial cells: involvement of PPAR-γ upregulation and PI3K, ERK1/2, and PKC signal pathways | |
| Zhou et al. | Antitumor activities of ginseng polysaccharide in C57BL/6 mice with Lewis lung carcinoma | |
| CN101007050B (en) | Extract of an traditional Chinese medicine containing isopsoralen, preparation method and use thereof | |
| Liu et al. | Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective | |
| CN106065023B (en) | Condensed tannin class compound, its medical composition and its use | |
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| Zhang et al. | Anti-tumor effect of matrine combined with cisplatin on rat models of cervical cancer | |
| Chen et al. | Pharmacological activities of safflower yellow and its clinical applications | |
| Zhao et al. | Anti-angiogenic effects of Qingdu granule on breast cancer through inhibiting NFAT signaling pathway | |
| US11007169B2 (en) | Cis-gnetin H and trans-gnetin H as therapeutic agents | |
| CN105726524A (en) | Use of diarylheptanoid compound in preparation of drug or food for preventing and treating psoriasis | |
| CN105732380A (en) | Diarylheptanoid compound and its preparation method and use | |
| Li et al. | Yin Yang Gong Ji pill is an ancient formula with antitumor activity against hepatoma cells | |
| Yang et al. | Brazilin inhibits the invasion and metastasis of breast cancer | |
| CN105732379A (en) | Diarylheptanoid compound and its preparation method and use | |
| CN102188502B (en) | Extraction method and composition of common souliea rhizome total saponins with anti-tumor effect | |
| CN102125589B (en) | Preparation method and use of active ingredients of red ginseng | |
| Quitain et al. | Microwave-assisted pressurized hot water Extraction of Alkaloids | |
| CN101829123A (en) | Application of | |
| CN104523675A (en) | Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis | |
| CN101292974B (en) | Pharmaceutical use of diacetyl diphenyl sulphone heptane in preventing and controlling chronic marrow-derived leukocythemia | |
| CN102824385A (en) | Aralia tengyuch euonymus bark total saponin and preparation method and application thereof | |
| US10329316B2 (en) | Phenylpropanoid compound and preparation method and use thereof | |
| CN103709015B (en) | Ginkgol C17:1 purposes in liver cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |